vs

Side-by-side financial comparison of ISABELLA BANK CORP (ISBA) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $21.2M, roughly 1.8× ISABELLA BANK CORP). On growth, ISABELLA BANK CORP posted the faster year-over-year revenue change (14.3% vs -57.1%). Over the past eight quarters, ISABELLA BANK CORP's revenue compounded faster (12.6% CAGR vs -46.5%).

The Bank of the Philippine Islands is a universal bank in the Philippines. It is the oldest bank in both the Philippines and Southeast Asia. It is the fourth largest bank in terms of assets, the second largest bank in terms of market capitalization, and one of the most profitable banks in the Philippines.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ISBA vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.8× larger
ORGO
$37.2M
$21.2M
ISBA
Growing faster (revenue YoY)
ISBA
ISBA
+71.3% gap
ISBA
14.3%
-57.1%
ORGO
Faster 2-yr revenue CAGR
ISBA
ISBA
Annualised
ISBA
12.6%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ISBA
ISBA
ORGO
ORGO
Revenue
$21.2M
$37.2M
Net Profit
$4.7M
Gross Margin
30.8%
Operating Margin
32.2%
-185.1%
Net Margin
22.2%
Revenue YoY
14.3%
-57.1%
Net Profit YoY
17.4%
EPS (diluted)
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ISBA
ISBA
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$21.2M
$225.6M
Q3 25
$20.5M
$150.9M
Q2 25
$18.8M
$101.0M
Q1 25
$18.1M
$86.7M
Q4 24
$18.5M
$126.7M
Q3 24
$18.0M
$115.2M
Q2 24
$17.2M
$130.2M
Net Profit
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
$4.7M
$43.7M
Q3 25
$5.2M
$21.6M
Q2 25
$5.0M
$-9.4M
Q1 25
$3.9M
$-18.8M
Q4 24
$4.0M
$7.7M
Q3 24
$3.3M
$12.3M
Q2 24
$3.5M
$-17.0M
Gross Margin
ISBA
ISBA
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
ISBA
ISBA
ORGO
ORGO
Q1 26
-185.1%
Q4 25
32.2%
28.1%
Q3 25
30.7%
13.7%
Q2 25
32.8%
-12.5%
Q1 25
26.9%
-30.9%
Q4 24
26.0%
8.1%
Q3 24
21.3%
5.4%
Q2 24
23.9%
-10.7%
Net Margin
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
22.2%
19.4%
Q3 25
25.6%
14.3%
Q2 25
26.7%
-9.3%
Q1 25
21.9%
-21.7%
Q4 24
21.6%
6.1%
Q3 24
18.2%
10.7%
Q2 24
20.3%
-13.1%
EPS (diluted)
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
$0.64
$0.31
Q3 25
$0.71
$0.11
Q2 25
$0.68
$-0.10
Q1 25
$0.53
$-0.17
Q4 24
$0.54
$0.05
Q3 24
$0.44
$0.09
Q2 24
$0.46
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ISBA
ISBA
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$26.0M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$231.4M
Total Assets
$2.2B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ISBA
ISBA
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$26.0M
$93.7M
Q3 25
$161.3M
$63.7M
Q2 25
$108.6M
$73.1M
Q1 25
$69.2M
$110.0M
Q4 24
$24.5M
$135.6M
Q3 24
$27.4M
$94.3M
Q2 24
$23.6M
$89.9M
Total Debt
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
$231.4M
$300.1M
Q3 25
$227.4M
$255.1M
Q2 25
$220.5M
$233.2M
Q1 25
$215.6M
$242.9M
Q4 24
$210.3M
$262.9M
Q3 24
$213.0M
$278.5M
Q2 24
$202.2M
$263.5M
Total Assets
ISBA
ISBA
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$2.2B
$598.7M
Q3 25
$2.3B
$509.8M
Q2 25
$2.2B
$461.1M
Q1 25
$2.1B
$467.4M
Q4 24
$2.1B
$497.9M
Q3 24
$2.1B
$446.3M
Q2 24
$2.1B
$443.2M
Debt / Equity
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ISBA
ISBA
ORGO
ORGO
Operating Cash FlowLast quarter
$26.8M
Free Cash FlowOCF − Capex
$23.3M
FCF MarginFCF / Revenue
110.2%
Capex IntensityCapex / Revenue
16.4%
Cash ConversionOCF / Net Profit
5.72×
TTM Free Cash FlowTrailing 4 quarters
$36.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
$26.8M
$39.4M
Q3 25
$2.7M
$3.1M
Q2 25
$7.8M
$-32.9M
Q1 25
$4.7M
$-19.9M
Q4 24
$19.6M
$10.9M
Q3 24
$3.6M
$8.7M
Q2 24
$5.5M
$4.7M
Free Cash Flow
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
$23.3M
$34.8M
Q3 25
$1.7M
$844.0K
Q2 25
$7.2M
$-36.5M
Q1 25
$3.7M
$-23.6M
Q4 24
$17.5M
$7.6M
Q3 24
$3.2M
$6.1M
Q2 24
$5.1M
$2.9M
FCF Margin
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
110.2%
15.4%
Q3 25
8.5%
0.6%
Q2 25
38.5%
-36.1%
Q1 25
20.6%
-27.2%
Q4 24
94.6%
6.0%
Q3 24
17.7%
5.3%
Q2 24
29.8%
2.2%
Capex Intensity
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
16.4%
2.1%
Q3 25
5.0%
1.5%
Q2 25
3.2%
3.6%
Q1 25
5.5%
4.2%
Q4 24
11.4%
2.7%
Q3 24
2.0%
2.2%
Q2 24
2.4%
1.4%
Cash Conversion
ISBA
ISBA
ORGO
ORGO
Q1 26
Q4 25
5.72×
0.90×
Q3 25
0.52×
0.14×
Q2 25
1.56×
Q1 25
1.19×
Q4 24
4.91×
1.43×
Q3 24
1.08×
0.71×
Q2 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons